Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: Effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 525-536

  Serpe, Loredana ^a   Laurora, Stefano ^a   Pizzimenti, Stefania ^a   Ugazio, Elena ^a   Ponti, Renata ^a   Canaparo, Roberto ^a   Briatore, Federica ^a   Barrera, Giuseppina ^a   Gasco, Maria Rosa ^a   Bernengo, Maria Grazia ^a   Eandi, Mario ^a   Zara, Gian Paolo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

c myc oncogene; Cell cycle; Cholesteryl butyrate; Sodium butyrate; Solid lipid nanoparticles

Indexed keywords

BUTYRIC ACID; LIPID;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYMPHOID CELL; NANOTECHNOLOGY; ONCOGENE MYC; PRIORITY JOURNAL; SOLID;

APOPTOSIS; BLOTTING, WESTERN; BUTYRIC ACIDS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL ESTERS; HL-60 CELLS; HUMANS; JURKAT CELLS; MICROSCOPY, FLUORESCENCE; NANOTECHNOLOGY; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; PRODRUGS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; U937 CELLS;

EID: 2942602846     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127329.83568.15     Document Type: Article

References (41)

1. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982; 42:65-82.
2. Pellizzaro C, Coradini D, Morel S, Ugazio E, Gasco MR, Daidone MG. Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res 1999; 19:3921-3926.
3. Coradini D, Pellizzaro C, Marimpietri D, Abolafio G, Daidone MG. Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell Prolif 2000; 33:139-146.
4. Gaschott T, Maassen CU, Stein J. Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells. Anticancer Res 2001; 21:2815-2819.
5. Ito N, Sawa H, Nagane M, Noguchi A, Hara M, Saito I. Inhibitory effects of sodium butyrate on proliferation and invasiveness of human glioma cells. Neurosurgery 2001; 49:430-436.
6. Archer S, Meng S, Wu J, Johnson J, Tang R, Hodin R. Butyrate inhibits colon carcinoma cell growth through two distinct pathways. Surgery 1998; 124:248-253.
7. Iacomino G, Tecce MF, Grímaldí C, Tosto M, Russo GL. Transcriptional response of a human colon adenocarcinoma cell line to sodium butyrate. Biochem Biophys Res Commun 2001; 285:1280-1289.
8. Krupitza G, Harant H, Ditrich E. Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells. Carcinogenesis 1995; 16:1199-1205.
9. Tang S, Huang YM, Wang FF. Analysis of c-fos expression in the butyrate-induced F98 glioma cell differentiation. Biochem J 1995; 306:47-56.
10. Smith JG, Yokoyama WH, German B. Butyric acid from the diet: actions at the level of gene expression. Rev Food Sci 1998; 38:259-297.
11. Kip1. Surgery 1998; 124:161-170.
12. WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001; 68:170-178.
13. Santini V, Scappini B, Grossi A, Villa P, Ronco G, Douillet O, et al. Butyrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukemia cells. Br J Hematol 1998; 101:529-538.
14. Santini V, Gozzini A, Scapini B, Caporale R, Zoccolante A, Rigacci L, et al. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells. Hematologia 1999; 84:897-904.
15. Novogrodsky A, Dvir A, Ravid A. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 1983; 51:9-14.
16. Miller AA, Kurschel E, Osieka R. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Clin Oncol 1987; 23:1283-1287.
17. Egorin MJ, Yuan ZM, Sent DL, Plaisance K, Eiseman JL. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 1999; 43:445-453.
18. Santini V, Gozzini A, Scappini B, Grossi A, Rossi Ferrini P. Searching for the magic bullet against cancer: the butyrate saga. Leuk Lymphoma 2001; 42:275-289.
19. Perrine SP, Dover GH, Daftari P, Walsh CT, Jin Y, Mays A, et al. Isobutyramide, and orally bioavailable butyrate analogue, stimulates fetal globine gene expression in vitro and in vivo. Br J Hematol 1994; 88:555-561.
20. Zara GP, Cavalli R, Fundarò A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res 1999; 40:281-286.
21. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53:283-318.
22. Ugazio E, Marengo E, Pellizzaro C, Coradini D, Peira E, Daidone MG, et al. The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-460 cell proliferation. Eur J Pharm Biopharm 2001; 52:197-202.
23. Salomone B, Ponti R, Gasco MR, Ugazio E, Quaglino P, Osella-Abate S, et al. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin Exp Metastasis 2001; 18:663-673.
24. Zhang JW, Wang JY, Chen SJ, Chen Z. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. J Biosci 2000; 25:275-284.
25. Lee MO, Kang HJ, Kim YM, Oum JH, Park J. Repression of FasL expression by retinoic acid involves a novel mechanism of inhibition of transactivation function of the nuclear factors of activated T-cells. Eur J Biochem 2002; 269:1162-1170.
26. CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta- arabinofuranosylcytosine. Differentiation 2000; 66:1-13.
27. Wrone-Smith T, Izban KF, Ergin M, Cosar EF, His ED, Alkan S. Transfection of caspase-3 in caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C induced apoptosis. Exp Hematol 2001; 29:572-581.
28. 2 and A cyclin expression in HL-60 cells by the lipid peroxidation product 4-hydroxynonenal. Free Rad Biol Med 1999; 26:1578-1586.
29. Melnick A, Licht JD. Histone deacetylases as therapeutic target in hematologic malignancies. Curr Opin Hematol 2002; 9:322-332.
30. Chen ZX, Breitman TR. Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 1994; 54:3494-3499.
31. Rephaeli A, Rabizadeh E, Aviram A, Shaklai M, Ruse M, Nudelman A. Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer 1991; 49:66-72.
32. Pouillart P, Cerutti I, Ronco G, Villa P, Chany C. Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy. Int J Cancer 1991; 49:889-895.
33. Gasco MR. Solid lipid nanoparticles for drug delivery. Pharm Tech Eur 2001; 13:32-42.
34. Fundarò A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Stealth and non-stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000; 42:337-343.
35. Zara GP, Bargoni A, Cavalli R, Fundarò A, Vighetto D, Gasco MR. Idarubicin solid lipid nanospheres administration to rats by duodenal route: pharmakokinetics and tissues distribution. J Pharm Sci 2002; 91:1324-1333.
36. Zara GP, Cavalli R, Bargoni A, Fundarò A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin loaded solid lipid nanoparticles at increasing concentration of stealth agent: pharmacokinetics and distribution in brain and other tissues. J Drug Target 2002; 10:327-335.
37. Bernhard D, Ausserlechner JM, Tonko M, Loffler M, Hartmann BL, Csordas A, et al. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J 1999; 13:1991-2001.
38. Calabresse C, Venturini L, Ronco G, Villa P, Degos L, Belpomme D, et al. Selective induction of apoptosis in myeloid leukemic cell lines by monoacetone glucose-3 butyrate. Biochem Biophys Res Commun 1994; 201:266-283.
39. Barrera G, Muraca R, Pizzimenti S, Serra A, Rosso C, Saglio G, et al. Inhibition of c-myc expression induced by α-hydroxynonenal, a product of lipid peroxidation, in the HL-60 human leukemic cell line. Biochem Biophys Res Commun 1994; 203:553-561.
40. Mariani MR, Carpaneto EM, Ulivi M, Allfrey VG, Boffa LC. Correlation between butyrate-induced histone hyperacetylation turn-over and c-myc expression. J Steroid Biochem Mol Biol 2003; 86:167-171.
41. Rabizadeh E, Shahlai M, Nudelman A, Eisenbach L, Rephaeli A. Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett 1993; 328:225-229.